Article
Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.
Alimentary pharmacology & therapeutics - 1 Jun 2008
Lim S G, Leung N, Hann H W L, Lau G K K, Trepo C, Mommeja-Marin H, Moxham C, Sorbel J, Snow A, Blum M R, Rousseau F, Marcellin P
Abstract excerpt
BACKGROUND: Clevudine is a polymerase inhibitor that has the unusual feature of delayed viral rebound after therapy in some patients which may be related to its pharmacokinetics. AIM: To characterize pharmacokinetic and pharmacodynamic profile of clevudine, a potent hepatitis B polymerase inhibitor. METHODS: A multicenter, randomized study comparing 10, 30 and 50 mg clevudine once daily for 12 weeks with 24 weeks...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.